share_log

This Insider Has Just Sold Shares In New Ray Medicine International Holding Limited (HKG:6108)

This Insider Has Just Sold Shares In New Ray Medicine International Holding Limited (HKG:6108)

這位內部人士剛剛出售了新光醫藥國際控股有限公司(HKG:6108)的股份
Simply Wall St ·  2022/05/16 18:27

Some New Ray Medicine International Holding Limited (HKG:6108) shareholders may be a little concerned to see that insider Wen Xiaodong recently sold a substantial HK$199m worth of stock at a price of HK$0.61 per share. Probably the most concerning element of the whole transaction is that the disposal amounted to 85% of their entire holding.

一些新光醫藥國際控股有限公司(HKG:6108)股東們看到內部人士温曉東最近以每股0.61港元的價格出售了價值1.99億港元的大量股票,可能會有點擔心。可能整個交易中最令人擔憂的因素是,出售的股份佔其全部持股的85%。

View our latest analysis for New Ray Medicine International Holding

查看我們對新光醫藥國際控股的最新分析

New Ray Medicine International Holding Insider Transactions Over The Last Year

新光醫藥國際控股公司去年的內幕交易

Notably, that recent sale by Wen Xiaodong is the biggest insider sale of New Ray Medicine International Holding shares that we've seen in the last year. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The good news is that this large sale was at well above current price of HK$0.31. So it may not shed much light on insider confidence at current levels.

值得注意的是,温曉東最近出售的股票是我們去年看到的最大規模的新光醫藥國際控股股份內幕交易。雖然我們通常不喜歡看到內幕出售,但如果以更低的價格出售,人們更擔心的是。好消息是,這筆大筆交易的價格遠高於目前0.31港元的價格。因此,在目前的水平上,這可能不會讓人對內部人士的信心有太多瞭解。

Wen Xiaodong bought a total of 597.74m shares over the year at an average price of HK$0.70. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

温曉東全年共買入5.9774億股,均價為0.70港元。你可以在下面看到過去12個月(由公司和個人)進行的內幕交易的直觀描述。如果你想知道到底是誰賣了,賣了多少錢,什麼時候賣的,只需點擊下面的圖表!

SEHK:6108 Insider Trading Volume May 16th 2022
聯交所:2022年5月16日內幕交易量6108

New Ray Medicine International Holding is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

新光醫藥國際控股並不是內部人士買入的唯一股票。對於那些想要找到贏得投資免費最近有內幕收購的不斷增長的公司名單可能就是合適的選擇。

Does New Ray Medicine International Holding Boast High Insider Ownership?

新光醫藥國際控股公司是否擁有高度的內部人持股?

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. New Ray Medicine International Holding insiders own 75% of the company, currently worth about HK$389m based on the recent share price. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

看看一家公司的內部人持股總數,可以幫助你瞭解他們是否與普通股股東很好地結合在一起。內部人持股比例較高往往會讓公司領導層更加關注股東利益。新光醫藥國際控股有限公司內部人士持有該公司75%的股份,按近期股價計算,目前價值約3.89億港元。大多數股東將樂於看到這種內部人持股,因為這表明管理層的激勵與其他股東很好地結合在一起。

What Might The Insider Transactions At New Ray Medicine International Holding Tell Us?

新光醫藥國際控股有限公司的內幕交易可能告訴我們什麼?

It is good to see the recent insider purchase. And an analysis of the transactions over the last year also gives us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about New Ray Medicine International Holding. That's what I like to see! So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. To assist with this, we've discovered 2 warning signs that you should run your eye over to get a better picture of New Ray Medicine International Holding.

很高興看到最近的內幕收購。對過去一年交易的分析也給了我們信心。然而,我們注意到該公司在過去12個月裏沒有盈利,這讓我們保持謹慎。除了高內部人持股,這一分析表明,內部人相當看好新光醫藥國際控股公司。這就是我想看到的!因此,雖然瞭解內部人士在買入或賣出方面做了什麼是有幫助的,但瞭解一家特定公司面臨的風險也是有幫助的。為了幫助這一點,我們發現2個警告標誌你應該掃視一下,才能更好地瞭解新光醫藥國際控股公司。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

當然了,如果你把目光投向別處,你可能會發現這是一筆很棒的投資。所以讓我們來看看這個免費有趣的公司名單。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

就本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前負責公開市場交易和私人處置,但不包括衍生品交易。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論